MDM2 and neuroblastoma: This study demonstrates for the first time the highly selective and potent in vitro anti-tumour activity of RG7388 as a single agent in p53 wt neuroblastoma of varying MYCN, MDM2 and p14ARF genetic status, resulting in p53 stabilisation and activation of the p53 pathway.